Top entities: BeOne Medicines, Revolution Medicines, John V. Oyler, Mark A. Goldsmith, Japan.

What category does this event fall under?

Business — classified as collaboration.

What is the sentiment of coverage?

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Revolution Medicines granted exclusive rights BeOne Medicines · BeOne Medicines signed collaboration Revolution Medicines

Is this event still developing?

This is an active story, last updated Aug 11, 2026. Coverage continues to evolve.

Business collaboration

BeOne and Revolution Medicines oncology collaboration

Q: When did this event occur?

First reported Aug 10, 2026; last updated Aug 11, 2026.

Q: What is the market impact?

General. The collaboration is expected to positively impact both companies by expanding Revolution Medicines' market reach into Asia and enhancing BeOne's oncology pipeline with promising RAS(ON) inhibitors.

Analysis based on 7 articles · First reported Aug 10, 2026 · Last updated Aug 11, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The collaboration is expected to positively impact both companies by expanding Revolution Medicines' market reach into Asia and enhancing BeOne's oncology pipeline with promising RAS(ON) inhibitors. Investors may view the deal favorably, potentially boosting stock prices for both companies due to the strategic value and potential milestone payments.

Biotechnology Pharmaceuticals

Event Summary

BeOne Medicines and Revolution Medicines announced a multi-part collaboration on August 10, 2026. The deal includes a clinical collaboration to evaluate drug combinations combining select BeOne oncology assets with Revolution Medicines' four clinical RAS(ON) inhibitors (daraxonrasib, zoldonrasib, elironrasib, and RMC-5127). Planned combination studies include BeOne's PRMT5 inhibitor BGB-58067 and EGFR x MET x MET trispecific antibody BG-T187 with either daraxonrasib or zoldonrasib. Additionally, a regional rights agreement grants BeOne exclusive development and commercialization rights to these four inhibitors in select Asian markets, excluding Japan and South Korea. Revolution Medicines is eligible for development and sales milestone payments and tiered royalties on net sales in the partnered region. BeOne will fund and conduct a global registrational Phase 3 study for one of Revolution Medicines' RAS(ON) inhibitors. The collaboration aims to expand the geographic reach of Revolution Medicines' therapies and explore novel combination strategies for RAS-addicted cancers.

Key Actions

90 Revolution Medicines granted exclusive rights BeOne Medicines

80 BeOne Medicines signed collaboration Revolution Medicines

Entities Involved

priv

BeOne Medicines

BeOne gains exclusive rights to develop and commercialize Revolution Medicines' RAS(ON) inhibitors in select Asian markets, strengthening its oncology portfolio and regional presence. It will also fund a Phase 3 study, leveraging its development capabilities.

Importance 100.0 Sentiment 60.0

stock

Revolution Medicines

Revolution Medicines expands its global reach through BeOne's regional infrastructure and receives milestone payments and royalties. It retains rights outside the licensed territories, including Japan and South Korea.

Importance 100.0 Sentiment 60.0

per

John V. Oyler

As CEO of BeOne, Oyler is a key figure in the collaboration, expressing optimism about the deal's potential to bring new medicines to patients.

Importance 30.0 Sentiment 40.0

per

Mark A. Goldsmith

As CEO of Revolution Medicines, Goldsmith highlights the strategic value of the collaboration in advancing RAS(ON) inhibitors globally.

Importance 30.0 Sentiment 40.0

cnt

Japan

Japan is excluded from the licensed territory, so Revolution Medicines retains development and commercial rights there, with no direct impact on the country.

Importance 10.0 Sentiment 0.0

cnt

South Korea

South Korea is also excluded from the licensed territory, with Revolution Medicines retaining rights, and no direct impact on the country.

Importance 10.0 Sentiment 0.0

Relationships

Japan strategic partner ↔ South Korea Japan views South Korea as a strategic partner with deepening security and economic cooperation, despite lingering histo

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard